600276 Stock Overview
A pharmaceutical company, develops, manufactures, and commercializes drugs worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
No risks detected for 600276 from our risk checks.
Jiangsu Hengrui Medicine Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥50.19 |
| 52 Week High | CN¥57.53 |
| 52 Week Low | CN¥35.51 |
| Beta | 0.29 |
| 11 Month Change | -1.12% |
| 3 Month Change | 15.06% |
| 1 Year Change | 6.40% |
| 33 Year Change | -5.28% |
| 5 Year Change | -19.41% |
| Change since IPO | 458.37% |
Recent News & Updates
Recent updates
Shareholder Returns
| 600276 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 3.6% | 1.0% | -0.9% |
| 1Y | 6.4% | -4.8% | 5.4% |
Return vs Industry: 600276 exceeded the CN Pharmaceuticals industry which returned -3.4% over the past year.
Return vs Market: 600276 matched the CN Market which returned 6.1% over the past year.
Price Volatility
| 600276 volatility | |
|---|---|
| 600276 Average Weekly Movement | 6.0% |
| Pharmaceuticals Industry Average Movement | 7.2% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CN Market | 12.6% |
| 10% least volatile stocks in CN Market | 5.6% |
Stable Share Price: 600276 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 600276's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1970 | 19,611 | Hong Bin Dai | www.hrs.com.cn |
Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, develops, manufactures, and commercializes drugs worldwide. The company is developing Camrelizumab, Pyrotinib, Fuzuloparib, Adebrelimab, Rezvilutamide, Famitinib, Dalpiciclib, SHR-1701, SHR-1501, SHR-A1811, SHR1459, Mecapegfilgrastim, Apatinib, Linperlisib, and SHR2554 for oncology indications; SHR4640, Retagliptin, SHR20004, SHR-1209, SHR3824, INS068, SHR7280, and SHR2285 for cardiovascular and metabolism indications. It is also developing SHR0302, Hetrombopag, Vunakizumab, and SHR-1703 for autoimmune indications; SHR0410, Imrecoxib, Remimazolam, and SHR8554 for pain; Oteseconazole and HRS9950 for anti-infection; and SHR8028, SHR8058, SHR-1707, and SHR-1222 for other indications.
Jiangsu Hengrui Medicine Co., Ltd. Fundamentals Summary
| 600276 fundamental statistics | |
|---|---|
| Market cap | CN¥319.14b |
| Earnings (TTM) | CN¥5.45b |
| Revenue (TTM) | CN¥26.00b |
58.6x
P/E Ratio12.3x
P/S RatioIs 600276 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600276 income statement (TTM) | |
|---|---|
| Revenue | CN¥26.00b |
| Cost of Revenue | CN¥3.74b |
| Gross Profit | CN¥22.26b |
| Other Expenses | CN¥16.81b |
| Earnings | CN¥5.45b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.86 |
| Gross Margin | 85.62% |
| Net Profit Margin | 20.96% |
| Debt/Equity Ratio | 0% |
How did 600276 perform over the long term?
See historical performance and comparison